Tinlarebant

Rx-BLTE-2702BLTE/FDA decisionResearch

Belite Bio · Stargardt disease type 1Feb 12, 2027 target

Will the FDA approve Tinlarebant for Stargardt disease type 1?

Drug profile Company Event Small moleculeNCT05244304

Primary source

YBLTE

BLTE-YES/ USDC

Outcome claim / Research candidate

NOT LISTED

Executable price

—

Change across observed prices in this window

Implied YES probability—Price-based, not a clinical forecast

Market not listed

No market price yet.

This program has no funded pool or observed trading history. Start with the evidence, or explore a clearly labeled scenario.

0 trading observationsNo live price feed

YES —NO —

This chart stays empty until observations exist. Research status is not an approval probability. A sandbox session creates a separate virtual price history.

Rx-BLTE-2702 / Evidence

Unlisted

Pool price—No deployed pool

Dated model P(YES)—No dated model artifact

Days to sponsor target102Date-only guidance

Source publishedAug 11, 2026

Research snapshotOct 28, 2026

FDA targetFeb 12, 2027

Small moleculeNCT05244304

A pool price describes trading inventory; a model estimates an outcome. Neither a live price nor a dated forecast is available for this unlisted catalyst.

Program overview

Sponsor reports NDA acceptance for tinlarebant in Stargardt disease and a February 12, 2027 FDA target.

THERAPEUTIC AREAOphthalmology

DRUG / PROGRAMTinlarebant

INDICATIONStargardt disease type 1

REGULATORY TARGETFebruary 12, 2027

Agent model / unavailable

No reviewed probability or reasoning artifact is available. A neutral pool opening is not a clinical base rate.

What matters

Pin age range, indication and approval definition; do not confuse US decision with Japanese or Access Consortium submissions.
Approval, the stock price and commercial success are different outcomes. A claim only pays on its specified event.
Future program funding and tokenized financing require separate rights and contracts. An event claim gives no equity, royalty or drug IP.

Try virtual trading